Company profile
Capricor Therapeutics, Inc.
Pipeline4 assets
- DeramiocelCAP-1002 / allogeneic CDCs / Neuromuscular diseaseDuchenne muscular dystrophy (DMD)Phase 3in progressBecker muscular dystrophy (BMD)Preclinicalin progress
- StealthX™STX-S / Exosome-based vaccine / Infectious diseaseSARS-CoV-2Phase 1in progress
- StealthX™Therapeutic ExosomesEvaluatingPreclinicalin progress
- CDC-ExosomesExosome Platform / Neuromuscular diseaseDuchenne muscular dystrophyPreclinicalin progress
Latest news18 items
All newsThe Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Trial Results • Phase 3Results event Wed, Jul 29, 2026, 10:05 AM EDT
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Presentation / Abstract • Phase 3Late-breaking presentation Sat, Jun 27, 2026